{
    "nct_id": "NCT04736706",
    "official_title": "An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)",
    "inclusion_criteria": "* Has histologically confirmed diagnosis of RCC with clear cell component.\n* Has received no prior systemic therapy for advanced ccRCC\n* Male participants are abstinent from heterosexual intercourse or agree to use contraception during and for at least 7 days after last dose of study intervention with belzutifan and lenvatinib.\n* Female participants are not pregnant or breastfeeding and are either not a woman of child-bearing potential (WOCBP) or use a contraceptive method that is highly effective or are abstinent from heterosexual intercourse during the intervention period and for at least 120 days after pembrolizumab or pembrolizumab/quavonlimab or for at least 30 days after last dose of lenvatinib or belzutifan, whichever occurs last\n* Has adequately controlled blood pressure with or without antihypertensive medications\n* Has adequate organ function.\n* Participants receiving bone resorptive therapy must have therapy initiated at least 2 weeks prior to randomization/allocation\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has had major surgery, other than nephrectomy within 4 weeks prior to randomization\n* Has known central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Has received prior radiotherapy within 2 weeks prior to first dose of study intervention\n* Has hypoxia or requires intermittent supplemental oxygen or requires chronic supplemental oxygen\n* Has clinically significant cardiac disease within 12 months from first dose of study intervention\n* Has a history of interstitial lung disease\n* Has symptomatic pleural effusion; a participant who is clinically stable following treatment of this condition is eligible\n* Has preexisting gastrointestinal or non-gastrointestinal fistula\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment\n* Has a known psychiatric or substance abuse disorder that would interfere with requirements of the study\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study drug; killed vaccines are allowed\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years\n* Has a history of noninfectious pneumonitis that required steroids or has current pneumonitis\n* Has an active infection requiring systemic therapy\n* Has a known history of human immunodeficiency virus (HIV) infection\n* Has a known history of Hepatitis B\n* Has radiographic evidence of intratumoral cavitation, encasement or invasion of a major blood vessel\n* Has clinically significant history of bleeding within 3 months prior to randomization\n* Has had an allogenic tissue/solid organ transplant",
    "miscellaneous_criteria": ""
}